• Testimonial: Dr. Monica Varun Tyagi
    Dr. Monica Varun Tyagi discusses her experience publishing “GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3,” with Oncotarget.
  • Behind the Study: P4HA1 Protein and Colorectal Cancer
    Dr. Michael Roehrl describes the research paper he co-authored that was published by Oncotarget, entitled, “Prolyl 4-hydroxylase alpha 1 protein expression risk-stratifies early stage colorectal cancer.”
  • Testimonial: Dr. Michael Roehrl
    Dr. Michael Roehrl discusses his experience while publishing the paper, “Prolyl 4-hydroxylase alpha 1 protein expression risk-stratifies early stage colorectal cancer,” with Oncotarget.

View All Posts >>


Visit this page to hear from the distinguished network of authors who continue to publish their research with Oncotarget—an open access biomedical journal dedicated to the bi-weekly publishing of the latest oncology-focused, peer-reviewed research papers. Here, readers will also find information about community news and events sponsored by Oncotarget.

For the latest summaries of new and trending Oncotarget papers,visit Oncotarget.org or ImpactJournals.com. Impact Journals is Oncotarget’s academic publisher. Read about our rigorous Scientific Integrity Process.


Oncotarget is published by Impact Journals of Orchard Park, New York. Impact Journals meets the standards established Wellcome Trust Publisher Requirements and is included on the Wellcome Trust List of Compliant Publishers.

Oncotarget is proud to have multiple Nobel Prize winning members on its editorial board, in addition to editors who have won the Lasker Prize and other prestigious recognitions. The open-access model employed by Oncotarget allows for free dissemination of thoroughly vetted peer-reviewed research material to the general public, leading to bigger and more frequent scientific breakthroughs. Because of Oncotarget’s uniquely varied scope, the journal has consistently published research on a wide range of subject areas, allowing readers to access an unparalleled diversity of knowledge in only one publication.

The founding editors of Oncotarget are Mikhail (Misha) Blagosklonny and Andrei Gudkov. Dr. Blagosklonny is well-known for his research in the field of aging, having published numerous papers on the subject. Mikhail is credited for advancing groundbreaking research of the drug Rapamycin, an anti-aging medicine that has shown to slow down the aging process. Having been featured in numerous publications on aging including a Scientific American article titled “A New Path to Longevity,” Mikhail continues to provide meaningfully important contributions to the scientific community.


Dr. Blagosklonny can be followed on Twitter @Blagosklonny and you can visit his website here.

To get in touch with Oncotarget, please visit our website. The journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.